Investor Relations, Email: ir@nuvoresearch.comCopyright CNW Group 2015
Nuvo Research® Announces 2015 Third Quarter Results
View original source (CNW)Nuvo Pharmaceuticals Inc on 6ix
Story so far
Earlier from Nuvo Pharmaceuticals
- Nuvo Research Announces Successful Pennsaid®2% Phase 3 Trial for Russia
- Nuvo Research® Announces Appointment to its Board of Directors
- Nuvo Research® Announces Intention to Split Into Two Publicly Traded Companies
- Nuvo Research® Announces U.S. Patent for Topical Foamed Formulations that Include DMSO
- Nuvo Research® Announces Grant of United States Patent for Topical Onychomycosis Formulation
Later from Nuvo Pharmaceuticals
- Nuvo Research® Announces TSX Conditional Approval to List Crescita Therapeutics Inc.
- Nuvo Research® Announces Acceleration of Expiry Date of Outstanding Warrants
- Nuvo Research® Provides Update on Pennsaid® 2% Phase 3 Clinical Trial
- Nuvo Research® Announces Special Shareholder Meeting to Vote on Reorganization of Nuvo into Two Publicly Traded Companies
- Nuvo Research® Reports Topline Results of Phase 2 Trial of WF10(TM) for the Treatment of Allergic Rhinitis
Follow Nuvo Pharmaceuticals into a list and get an email when it puts out news.
Follow Nuvo Pharmaceuticals